H Q Li1, C F Lu1, J Wang1, G P Yin1, R Sun1, X H Xu1, B L Liu1, F F Li1, T Jing1, K O Lee2, L Ye3, J H Ma4, X F Su5. 1. Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing, 210029, China. 2. Division of Endocrinology, Department of Medicine, National University of Singapore, Singapore, Singapore. 3. National Heart Research Institute Singapore, National Heart Centre Singapore, Singapore, Singapore. 4. Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing, 210029, China. majianhua@china.com. 5. Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing, 210029, China. suxiaofeifei@126.com.
Abstract
AIM: To determine the clinical non-inferiority of recombinant glargine-Basalin vs glargine-Lantus, in treatment of type 2 diabetes mellitus (T2DM) using continuous glucose monitoring system (CGMS). METHODS:One hundred patients with T2DM were recruited. They were either regularly taking Basalin (Basalin group) or Lantus (Lantus group) (n = 50 each). CGMS was employed to real-time monitor blood glucose profile for 4 days (from day 1 to day 5). To exclude the effect of patient background, the study design was to have a blinded crossover from glargine-Basalin to glargine-Lantus on day 3, and vice versa. 24-hour mean blood glucose (24hMBG), 24-hour standard deviation of blood glucose (24hSDBG), 24-hour mean amplitude of glycemic excursion (24hMAGE), and number of glycemic excursion (NGE) every 24 h (24hNGE) were calculated for each glargine from 100 patients. RESULTS: No significant difference of 24hMBG, 24hSDBG, 24hMAGE, and 24hNGE (p > 0.05 for all) was found between Basalin and Lantus treatments. The glucose area under the curve and time when blood glucose was below 3.9 mmol/L, between 3.9 and 10.0 mmol/L, or above 10.0 mmol/L were similar between Basalin and Lantus treatment. The frequency of hypoglycemic episodes was also similar. However, the mean cost of Basalin was only 72% of Lantus's in one treatment course. CONCLUSION:Glargine-Basalin is non-inferior in clinical efficacy compared to glargine-Lantus. In view of the large difference in the cost of glargine-Basalin, it would be much more cost-effective for our patients.
RCT Entities:
AIM: To determine the clinical non-inferiority of recombinant glargine-Basalin vs glargine-Lantus, in treatment of type 2 diabetes mellitus (T2DM) using continuous glucose monitoring system (CGMS). METHODS: One hundred patients with T2DM were recruited. They were either regularly taking Basalin (Basalin group) or Lantus (Lantus group) (n = 50 each). CGMS was employed to real-time monitor blood glucose profile for 4 days (from day 1 to day 5). To exclude the effect of patient background, the study design was to have a blinded crossover from glargine-Basalin to glargine-Lantus on day 3, and vice versa. 24-hour mean blood glucose (24hMBG), 24-hour standard deviation of blood glucose (24hSDBG), 24-hour mean amplitude of glycemic excursion (24hMAGE), and number of glycemic excursion (NGE) every 24 h (24hNGE) were calculated for each glargine from 100 patients. RESULTS: No significant difference of 24hMBG, 24hSDBG, 24hMAGE, and 24hNGE (p > 0.05 for all) was found between Basalin and Lantus treatments. The glucose area under the curve and time when blood glucose was below 3.9 mmol/L, between 3.9 and 10.0 mmol/L, or above 10.0 mmol/L were similar between Basalin and Lantus treatment. The frequency of hypoglycemic episodes was also similar. However, the mean cost of Basalin was only 72% of Lantus's in one treatment course. CONCLUSION:Glargine-Basalin is non-inferior in clinical efficacy compared to glargine-Lantus. In view of the large difference in the cost of glargine-Basalin, it would be much more cost-effective for our patients.
Authors: Xian Ling Wang; Ju Ming Lu; Chang Yu Pan; Yi Ming Mu; Jing Tao Dou; Jian Ming Ba; Xuemin Wang Journal: Diabetes Res Clin Pract Date: 2006-09-15 Impact factor: 5.602
Authors: Denisa Janickova Zdarska; Milan Kvapil; Zdenek Rusavy; Michal Krcma; Jan Broz; Bohumila Krivska; Pavla Kadlecova Journal: Wien Klin Wochenschr Date: 2014-02-22 Impact factor: 1.704
Authors: Goodarz Danaei; Carlene M M Lawes; Stephen Vander Hoorn; Christopher J L Murray; Majid Ezzati Journal: Lancet Date: 2006-11-11 Impact factor: 79.321